Adjuvant immunotherapy after kidney cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 trial studies additional (adjuvant) treatment after kidney cancer surgery, to lower the chance the cancer comes back. It tests immunotherapy drugs (durvalumab and tremelimumab) in people whose scans show no visible remaining cancer after operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had kidney cancer removed and the cancer was confirmed under the microscope (except certain rare types like pure oncocytoma, collecting duct, medullary, or transitional cell cancer).
- Your most recent CT scan shows no visible remaining (macroscopic) cancer after surgery.
- Your surgery must have been between 28 and 91 days before randomization, and you had post-op scans within 28 days before randomization.
- Your tumor risk level must match the trial’s “Leibovich score” range (3–11), as decided at the start of recruitment.
- You must be 18+ and healthy enough for treatment tests: good blood counts, liver labs, and kidney function, and an ECG with QTcF under 450 ms.
- You must be able to provide stored tumor tissue and a baseline blood sample, and agree to follow contraception rules (and not breastfeed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial tests a tool that helps decide whether people with stage III papillary kidney cancer should get a drug called pembrolizumab (immunotherapy) after surgery. The goal is to see if it lowers the chance of cancer coming back compared to no extra treatment.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with advanced kidney cancer that has returned after they previously received pembrolizumab as an adjuvant (preventive) treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.